Light & Wonder (NASDAQ:LNW) Azioni

LIGHT & WONDER INC

Light & Wonder

Light & Wonder is principally an electronic gaming machine manufacturer, selling machines to pubs, clubs, and casinos. The firm is licensed in most jurisdictions allowing gambling globally. Light & Wonder is one of the three largest players in the space along with International Game Technology and Aristocrat Leisure. SciPlay, about one fourth of revenue, develops and distributes casual mobile games, principally in the social casino niche. The more nascent iGaming business sits between these two businesses, providing digital content and capabilities to real-money gaming providers.

Light & Wonder Inc

SAVANNAH GOLDFIELDS LTD by SAVANNAH GOLDFIELDS LTD

WIIM

TSHA

Taysha Gene Therapies shares are trading higher. The company announced a proposed public offering of common stock.

News

C3 AI And Baker Hughes Renew And Expand Joint Venture Through June 2028 To Accelerate AI-Driven Transformation In Energy And Industrial Sectors

Management

JACK

Jack in the Box Appoints Dawn Hooper As Its CFO

C3.ai shares are trading higher after the company reported Q4 financial results and beat its adjusted EPS and revenue estimates.

– PGN-EDO51 did not achieve target dystrophin levels in CONNECT1-EDO51 trial; Company to discontinue development of DMD programs –
– PGN-EDO51 at 10 mg/kg was generally well tolerated; all treatment-related adverse events were mild –
– DM1 program on track to read out FREEDOM-DM1 15 mg/kg cohort in second half of 2025 and FREEDOM2-DM1 5 mg/kg cohort in Q1 2026 –
PepGen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEPG#NASDAQ">PEPG</a>), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies, today announced that based on the levels of dystrophin protein measured in the 10 mg/kg cohort of its CONNECT1-EDO51 study investigating PGN-EDO51 in Duchenne muscular dystrophy (DMD) patients amenable to exon 51 skipping, the Company will focus on advancing its promising myotonic dystrophy type 1 (DM1) program currently in Phase 2 clinical development. The Company is voluntarily discontinuing development of PGN-EDO51 and intends to wind down all DMD-related research and development activities.
In the 10 mg/kg cohort (n=4) of the CONNECT1 study, PGN-EDO51 increased exon 51 skipped transcripts to 4.26% (a mean increase of 3.5%); however, total dystrophin only increased to 0.59% of normal levels (a mean increase of 0.36%). The safety profile of PGN-EDO51 continued to be generally favorable and all treatment-related adverse events were mild in nature. No serious adverse events were reported in the study.

PEPG

PepGen Shifts Focus To DM1 Program Following CONNECT1-EDO51 Dystrophin Data

Guidance

e.l.f. Beauty Announces That Due To The Wide Range Of Potential Outcomes Related To Tariffs The Company Is Not Providing A Fiscal 2026 Financial Outlook At This Time

e.l.f. Beauty shares are trading lower following Q4 reported financial results.

C3 AI And Baker Hughes Renew And Expand Joint Venture Agreement Through 2028

Salesforce Raises FY2026 GAAP EPS Guidance from $6.95-$7.03 to $7.15-$7.21 vs $7.24 Est; Raises FY2026 Sales Guidance from $40.50B-$40.90B to $41.00B-$41.30B vs $40.83B Est

C3.ai (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AI#NYSE">AI</a>) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.20) by 20 percent. This is a 45.45 percent decrease over losses of $(0.11) per share from the same period last year. The company reported quarterly sales of $108.70 million which beat the analyst consensus estimate of $107.73 million by 0.90 percent. This is a 25.53 percent increase over sales of $86.59 million the same period last year.

Earnings

Earnings Beats

C3.ai Q4 Adj. EPS $(0.16) Beats $(0.20) Estimate, Sales $108.70M Beat $107.73M Estimate

Salesforce shares are trading higher after the company reported better-than-expected Q1 financial results.

Salesforce Sees Q2 GAAP EPS $1.80-$1.82 vs $1.71 Est; Sees Sales $10.110B-$10.160B vs $10.01B Est

Triumph Group Q4 Adj. EPS $0.48 Beats $0.35 Estimate, Sales $377.90M Beat $337.98M Estimate

Pure Storage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSTG#NYSE">PSTG</a>) sees FY2026 sales of $3.515 billion vs $3.51 billion analyst estimate.

PSTG

Pure Storage Sees FY2026 Sales $3.515B vs $3.51B Est

JPMorgan analyst Pinjalim Bora maintained a Neutral rating on GitLab Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTLB#NASDAQ">GTLB</a>) and set a <a href="https://in.benzinga.com/quote/GTLB/analyst-ratings" target="_blank" rel="noreferrer noopener">price target of $58</a> on Wednesday.
Bora is tactically positive going into the first quarter, largely because the stock has lagged the broader market while GitLab&#8217;s demand trends are likely stable.
The analyst expects a normal beat cadence, similar to the last few quarters, driving high 20% growth, partially aided by pricing benefits.
Also Read: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45551481/palo-altos-ai-momentum-make-it-a-top-cybersecurity-pick-analyst-says" target="_blank" rel="noreferrer noopener">Palo Alto&#8217;s AI Momentum Make It A Top Cybersecurity Pick, Analyst Says</a>
Additionally, he expects the company to maintain a conservative guidance posture and likely guide the second quarter much closer to the pin while flowing in the first-quarter beat into the full year.
Finally, Bora noted there is likely to be a decent amount of cushion on the profitability side, as he estimated headcount growth exiting the first quarter, running slightly below consensus operating expenditure growth assumptions for fiscal 2026.
At the same time, the analyst is slightly cautious of the refinements around sales and GTM that the new CRO might put in place, both across new customer acquisition and expansion plays. Bora is also unsure how to interpret the pricing and packaging changes.
While Bora appreciated GitLab&#8217;s continuous innovation and strategic role in the software development value chain, he maintained his Neutral rating due to the challenges posed by Agentic AI&#8217;s impact on developer headcount and evolving competition in the DevSecOps space.
In May, Bora noted some pricing and packaging changes, including promotions around the Premium SKU and packaging changes around AI capabilities.
GitLab has updated its pricing promotions around the Premium SKU. The analyst noted that these promotions have been in effect at least since the second half of calendar 2024 and were largely focused on smaller companies as GitLab tests the price sensitivity of its low-end customer base.
Concerning pricing on its AI-related SKUs, Bora noted that with the launch of GitLab 18, the company seems to be folding the AI-code suggestion capabilities, along with Duo Chat into the existing pricing constructs of Premium and Ultimate SKUs, for both Cloud and Self-managed customers, essentially offering them for free. 
The analyst noted that this compares to these AI features previously being part of the paid add-ons. Additionally, the company is relaxing the purchase requirements around Duo enterprise, allowing even Premium SKU customers to buy that AI SKU versus previously, which was limited to only Ultimate SKU customers, he said.
Analyzing website traffic to GitLab.com as a signal for top-of-the-funnel trends for GitLab, Bora noted a deceleration in both total visitor growth and unique visitor growth for the three months ending April (or fiscal first quarter), as compared to the previous quarter. More specifically, total visitors declined -17% Y/Y in the fiscal first quarter (versus -16% last quarter), while unique visitors declined -24% in the fiscal first quarter (versus -15% last quarter).
Based on data from LinkedIn, Bora noted that GitLab&#8217;s Y/Y total headcount growth remained relatively stable in April (at +17% Y/Y versus ~17% in January or fiscal fourth quarter), while sales headcount growth marked a slight uptick in April (+2% versus -1% in January or fiscal fourth quarter).
GitLab projected first-quarter revenue of $213 million and adjusted EPS of 14 cents..
GTLB Price Action: GitLab stock is down 3.65% at $46.25 at market close on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/media/25/05/45634446/microsoft-pulls-ahead-in-ai-race-with-key-partnerships-across-openai-nvidia-and-elon-musks-xai" target="_blank" rel="noreferrer noopener">Microsoft Pulls Ahead In AI Race With Key Partnerships Across OpenAI, Nvidia, And Elon Musk&#8217;s xAI</a></li>
</ul>
Photo: Lori Butcher via Shutterstock

Price Target

Reiteration

Analyst Ratings

Tech

Trading Ideas

GTLB

GitLab's AI Pricing Changes, CRO Strategy Make JPMorgan Analyst Cautious Despite Expected Q1 Beat

e.l.f. Beauty Q4 Adj. EPS $0.78 Beats $0.72 Estimate, Sales $332.64M Beat $327.47M Estimate

NTNX

Nutanix Expects Q4 Revenue Of $635M - $645M; Sees FY25 Revenue Of $2.52B - $2.53B

Earnings Misses

VEEV

Veeva Sys Q1 Adj. EPS $1.37 Misses $1.74 Estimate, Sales $759.00M Beat $731.91M Estimate

Agilent Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/A#NYSE">A</a>) affirms FY2025 Adj EPS guidance from $5.54-$5.61 to $5.54-$5.61 vs $5.55 analyst estimate. Raises FY2025 sales outlook from $6.68 billion-$6.76 billion to $6.73 billion-$6.81 billion vs $6.73 billion estimate.

Agilent Technologies Affirms FY2025 Adj EPS Guidance of $5.54-$5.61 vs $5.55 Est; Raises FY2025 Sales Guidance from $6.68B-$6.76B to $6.73B-$6.81B vs $6.73B Est

Agilent Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/A#NYSE">A</a>) is looking for Q3 Adj EPS of $1.35-$1.37 vs $1.39 analyst estimate. sees sales of $1.645 billion-$1.675 billion vs $1.65 billion analyst estimate.

Agilent Technologies Sees Q3 Adj EPS $1.35-$1.37 vs $1.39 Est; Sees Sales $1.645B-$1.675B vs $1.65B Est

Press Releases

Light & Wonder Provides Update on Dragon Train Litigation

Light & Wonder to Report First Quarter 2025 Results on Wednesday, May 7, 2025

Light & Wonder to Host Investor Day on Tuesday, May 20, 2025

Rosen Law Firm Encourages Light & Wonder, Inc. Investors to Inquire About Securities Class Action Investigation - LNW

Legal

Light & Wonder, Inc. Investor News: If You Have Suffered Losses in Light & Wonder, Inc. (NASDAQ: LNW), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

LNW Investor News: Rosen Law Firm Encourages Light & Wonder, Inc. Investors to Inquire About Securities Class Action Investigation - LNW

LNW Investor News: If You Have Suffered Losses in Light & Wonder, Inc. (NASDAQ: LNW), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

Light & Wonder, Inc. Reports First Quarter 2025 Results

Light & Wonder Completes Acquisition of Grover Gaming's Charitable Gaming Assets

Light & Wonder Shares Multi-Year Growth Strategy at 2025 Investor Day

Accel Entertainment

PlayAGS

Ballys

Boyd Gaming

Codere Online Luxembourg, S.A. - Ordinary Shares

Codere Online Luxembourg

Churchill Downs, Incorporated - Common Stock

Churchill Downs

Canterbury Park Holding Corporation - Common Stock

Canterbury Park Holding

Caesars Entertainment, Inc. - Common Stock

Caesars Entertainment

DraftKings

Everi Holdings

Full House Resorts

Golden Entertainment, Inc. - Common Stock

Golden Entertainment

Genius Sports

International Game Technology Ordinary Shares

Intl Game Tech

Inspired Entertainment, Inc. - Common Stock

Inspired Entertainment

Las Vegas Sands

Monarch Casino & Resort, Inc. - Common Stock

Monarch Casino & Resort

MGM Resorts International

Melco Resorts & Entertainment Limited - American Depositary Shares

Melco Resorts and Enter

Studio City International Holdings Limited American depositary shares, each representing four Class A ordinary shares

Comments

Light & Wonder

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO